Milestone Pharmaceuticals is a cardiovascular drug development company developing a novel short-acting treatment for acute cardiac arrhythmias. Milestone’s lead product (MSP-2017) is a novel and potent short-acting calcium channel antagonist in preclinical development for acute paroxysmal supraventricular tachycardia (PSVT). The product is designed to be self-administered by patients to terminate acute PSVT episodes at-home in an unmonitored setting. Milestone’s business strategy is to identify a pharma partner and complete a transaction either at the end of the Ph 1 or Ph 2 studies.

Related news:

• Milestone Pharmaceuticals Announces $13 Million Equity Financing
• Milestone Pharmaceuticals
• Milestone Pharmaceutiques annonce un financement par actions de 13 millions de dollars
• Mimetogen Pharmaceuticals Completes Key Equity Financing
• Mimetogen Pharmaceuticals Inc. Closes Series A Financing and Completes Exclusive Licensing Agreement with McGill University